Clinical Trial Update: n-3 PUFA for Vascular Cognitive Aging [Phase 2]

View source ↗

Summary

Phase 2 trial update on n-3 polyunsaturated fatty acids for vascular cognitive aging, with conditions including age-related cognitive decline and Alzheimer's di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Cognitive Decline
• Alzheimer Disease
• Endothelial Dysfunction
• Executive Dysfunction
• Vascular Dementia

Drugs mentioned

• N-3 PUFA (omega-3 polyunsaturated fatty acids)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Age Related Cognitive Decline, Alzheimer's Disease | Phase 2 | Status: UNKNOWN